RecruitingNot ApplicableNCT06689241

Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery

Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial

Sponsor

Alexandria University

Enrollment

162 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Bariatric Surgery Candidate Morbid Obesity

Summary

Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open\_label randomized controlled trial

Eligibility

Min Age: 20 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Enoxaparin and a drug called rivaroxaban for people with bariatric surgery candidate and morbid obesity. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.